Publications by authors named "Gen-Hong Di"

Claim this Profile
S
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Xi-Yu Liu, Xin-Yi Sui, Ying Xu, Fan Yang, Song-Yang Wu, Ding Ma, Gen-Hong Di

Mol Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer.
Li Chen, Shu-Hao Jiang, Guang-Yu Liu, Ke-Da Yu, Jiong Wu, Gen-Hong Di

Mol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.
Li Chen, Wen-Ya Wu, Fei Liang, Guang-Yu Liu, Ke-Da Yu, Gen-Hong Di

Cancer Commun (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
Min He, Yi-Zhou Jiang, Yue Gong, Lei Fan, Xi-Yu Liu, Gen-Hong Di

BMJ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.
Min He, Shuang Hao, LinXiaoxi Ma, BingQiu Xiu, BenLong Yang, GenHong Di

EClinicalMedicine· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, Song-Yang Wu, Jiong Wu, Gen-Hong Di

Lancet Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.
Wen-Jia Zuo, Li Chen, Yu Shen, Zhong-Hua Wang, Guang-Yu Liu, Gen-Hong Di

Ther Adv Med Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.
Li-Ping Ge, Xi Jin, Ding Ma, Zi-Yu Wang, Cheng-Lin Liu, Gen-Hong Di

Cell Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
Jia-Han Ding, Yi Xiao, Fan Yang, Xiao-Qing Song, Ying Xu, Xiao-Hong Ding, Rui Ding, Gen-Hong Di

Sci Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities.
Chao Chen, Cai-Jin Lin, Yu-Chen Pei, Ding Ma, Li Liao, Gen-Hong Di

Cell Discov· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies.
Cai-Jin Lin, Wen-Xuan Xiao, Tong Fu, Xi Jin, Zhi-Ming Shao, Gen-Hong Di

NPJ Breast Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trial.
Yue Gong, Hua Zuo, Ying Zhou, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di

Ann Transl Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Fei-Lin Qu, Cai-Jin Lin, Zhe-Bin Liu, A-Yong Cao, Jiong Wu, Gen-Hong Di

Breast Cancer Res Treat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression.
Yun-Song Yang, Xi Jin, Qin Li, Yi-Yu Chen, Fenfang Chen, Gen-Hong Di

Proc Natl Acad Sci U S A· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, Jiong Wu, Gen-Hong Di

Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo multidimensional CRISPR screens identify as an immunotherapy target in triple-negative breast cancer.
Peng Ji, Yue Gong, Ming-Liang Jin, Huai-Liang Wu, Lin-Wei Guo, Gen-Hong Di

Sci Adv· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer.
Jia-Han Ding, Yi Xiao, Shen Zhao, Ying Xu, Yu-Ling Xiao, Gen-Hong Di

Mol Ther Oncolytics· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Tian-Jian Yu, Ying-Ying Liu, Xiao-Guang Li, Bi Lian, Xun-Xi Lu, Gen-Hong Di

Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
Yi-Fan Zhou, Yi Xiao, Xi Jin, Gen-Hong Di, Yi-Zhou Jiang

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.
Fei-Lin Qu, Rui Mao, Zhe-Bin Liu, Cai-Jin Lin, A-Yong Cao, Gen-Hong Di

Front Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers.
Tian-Jian Yu, Ding Ma, Ying-Ying Liu, Yi Xiao, Yue Gong, Gen-Hong Di

Mol Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial.
Ke-Da Yu, Xi-Yu Liu, Li Chen, Miao Mo, Jiong Wu, Gen-Hong Di, Armando Orlandi

Lancet Reg Health West Pac· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
Li-Ping Ge, Xi Jin, Yun-Song Yang, Xi-Yu Liu, Zhi-Ming Shao, Gen-Hong Di

Oncogene· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Yi-Zhou Jiang, Li-Ping Ge, Xi Jin, Lei Fan, Min He, Gen-Hong Di

Breast Cancer Res Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Guan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, Fan Yang, Xiao-Guang Li, Ding Ma, Gen-Hong Di

Nat Commun· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis